C100 derived from chitin shows promise in cancer immunotherapy

Summary: Scientists at Trinity College Dublin discovered that the vaccine adjuvant C100, derived from chitin, promotes potent anti-tumour immunity when injected into tumors. Published in Cell Reports Medicine, the study reveals C100's ability to activate a specific signaling pathway without causing inflammation. The research suggests C100 could enhance cancer immunotherapies, potentially improving response rates and offering hope for future immune therapies.

Full article